Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Endometrial cancer #NCT04590326
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Regeneron Pharmaceuticals
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04590326
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Regeneron Pharmaceuticals
Phase 1 / Phase 2 Colon cancer Rectal cancer Pancreas cancer Ovarian / Fallopian tubes / Peritoneum cancer Skin cancer #NCT07688148 #2025-521164-36-00
Required histologic types
Melanoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Apmonia Therapeutics
Phase 1 / Phase 2 Liver and bile duct cancer #NCT06330064 #2023-509632-26-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required BCLC stage (Barcelona Clinic Liver Cancer)
B C
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Breast cancer #NCT06330064 #2023-509632-26-00
Required HER2 statuses
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Breast cancer #NCT06330064 #2023-509632-26-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Skin cancer #NCT06330064 #2023-509632-26-00
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma Lentigo maligna melanoma Superficial spreading melanoma Acral lentiginous melanoma Achromic melanoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07213609 #2025-522318-21
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Colon cancer Rectal cancer Endometrial cancer #NCT07213609 #2025-522318-21
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Lung cancer Prostate cancer Bladder / Urinary Tract / Urethral cancer #NCT05875168 #2023-507937-14-00
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
5 recruiting sites
Daiichi Sankyo